Abstract
Background and Objective Point-of-care type molecular diagnostic tests have been used for detecting SARS-CoV-2, although their clinical utility with nasal samples has yet to be established. This study evaluated the clinical performance of the cobas Liat SARS-CoV-2 & Influenza AB (Liat) in nasal samples.
Methods Nasal and nasopharyngeal samples were collected and were tested using the Liat, the cobas 6800 system and the cobas SARS-CoV-2 & Influenza AB (cobas), and a method developed by National Institute of Infectious Diseases, Japan (NIID).
Results A total of 814 nasal samples were collected. The Liat assay was positive for SARS-CoV-2 in 113 (13.9%). The total, positive, and negative concordance rate between the Liat and cobas/NIID assays were 99.3%/98.4%, 99.1%/100%, and 99.3%/98.2%, respectively. Five samples were positive only using the Liat assay. Their Ct values ranged from 31.9 to 37.2. The Ct values of the Liat assay were significantly lower (p < 0.001) but were correlated (p < 0.001) with those of other molecular assays. In the participants who tested positive for SARS-CoV-2 on the Liat assay using nasopharyngeal samples, 88.2% of their nasal samples also tested positive using the Liat assay.
Conclusion The Liat assay showed high concordance with other molecular assays in nasal samples. Some discordance occurred in samples with Ct values > 30 on the Liat assay.
Key Points
The cobas Liat SARS-CoV-2 & Influenza AB assay showed high concordance with other molecular assays in nasal and nasopharyngeal samples, providing results within 20 minutes.
Some discordance occurred in samples with Ct values > 30 on the Liat assay.
The Liat assay may be suitable for use in a variety of clinical situations, primarily where accurate detection of SARS-CoV-2 is necessary.
Competing Interest Statement
Roche Diagnostics K.K., provided support in the form of salaries to author Michiko Horie, Kenichi Togashi, and Yuki Adachi. Molecular examinations using Liat, cobas, NIID, and Xpert Xpress were performed with financial support from Roche Diagnostics K.K. Hiromichi Suzuki was awarded lecture fee from Roche Diagnostics K.K.
Funding Statement
This study was financially supported by Roche Diagnostics K.K.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was performed in accordance with the principles of the Declaration of Helsinki and with the STROBE guidelines and was approved by the ethics committee of the University of Tsukuba (approval number: R03-41).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ E-mail addresses Michiko Horie, michiko.horie{at}roche.com; Junichi Kiyotaki, kiyo40324032{at}gmail.com; Yuto Takeuchi, yuto-Takeuchi{at}umin.ac.jp; Kenichi Togashi, kenichi.togashi{at}roche.com; Yuki Adachi, yuki.adachi{at}roche.com; Atsuo Ueda, atsuo.ueda06090727{at}outlook.jp; Shigeyuki Notake, notake{at}tmch.or.jp; Koji Nakamura, koji-nakamura{at}tmch.or.jp; Norihiko Terada, terada.norihiko.ck{at}ms.hosp.tsukuba.ac.jp; Yoko Kurihara, kurihara.yoko.fu{at}un.tsukuba.ac.jp; Yoshihiko Kiyasu, kiyasu-tuk{at}umin.ac.jp; Hiromichi Suzuki, hsuzuki{at}md.tsukuba.ac.jp
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos